CA-GUARDANT-HEALTH
15.9.2021 10:02:09 CEST | Business Wire | Press release
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, share data highlighting molecular targets of importance, treatment resistance patterns, and advantages of using the Guardant360® liquid biopsy test to help improve the management of advanced solid cancers at the European Society for Medical Oncology (ESMO) 2021 virtual congress on September 16-21.
“While precision oncology has made a meaningful difference in improving clinical outcomes for highly prevalent cancers, such as non-small cell lung, colorectal, and breast, there remains a subset of patients who don’t respond to currently available treatments,” said Craig Eagle, MD, Guardant Health Chief Medical Officer. “It is gratifying to be able to work with the oncology community to analyze the molecular information generated from our liquid biopsy tests to continue to increase our understanding of possible new targets and more personalized treatments which can potentially improve overall survival of these hard-to-treat cancers in a more meaningful way.”
Guardant INFORM™ Liquid Biopsy Dataset Shows No Clear Standard of Care and Unmet Need for Patients with HER2+ Metastatic Colorectal Cancer
Title |
ePoster |
Presenter |
Characteristics and treatment patterns among patients with HER2-amplified advanced/metastatic colorectal cancer (mCRC): A clinical-genomic database study |
439P |
John Strickler |
Guardant360® Liquid Biopsy Reveals Molecular Insights Impacting Outcomes in Patients with Unresectable and Early-Onset (<50 years) Metastatic Colorectal Cancer
Title |
ePoster |
Presenter |
Molecular features in liquid biopsy of early (EO) and late-onset colorectal cancer (LO) |
500P |
Julia Alcaide-Garcia |
Mutational landscape in synchronous unresectable metastatic colorectal cancer (mCRC) according to upfront primary tumour resection (UPTR) |
503P |
Manuel Benavides |
Guardant360® Liquid Biopsy Reveals Treatment Resistance Patterns and Therapeutic Targets for the Management of Advanced Cancers Including Non-Small Cell Lung and Pancreatic
Title |
ePoster |
Presenter |
First-results of the CLIMB360 study, a prospective molecular screening program across multiple cancer types based on circulating tumor DNA (ctDNA) |
92P |
Javier Garcia-Corbacho |
Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC) |
1196P |
Ben J. Solomon |
Cell-free DNA dominant clone allele frequency associates with poor outcomes in advanced pancreatic cancer |
1483P |
Pedro Uson Junior |
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360® , Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2020 and in its other reports filed with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for the periods ended March 31, 2021 and June 30, 2021. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005307/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Viz.ai Launches Viz Pulmonary Suite, the First Comprehensive AI-Powered Solution Dedicated to Pulmonary Care Delivery14.5.2026 15:00:00 CEST | Press release
Early Results Demonstrate Reduced Time to Treatment and Improved Patient Outcomes Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of the Viz Pulmonary™ Suite, an integrated AI-powered solution in the Viz.ai enterprise platform, designed to help health systems streamline care delivery for pulmonary conditions. The suite brings acute and chronic pulmonary workflows together in a single solution, giving clinicians a more streamlined way to manage patients to help get them on guideline-directed care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514994555/en/ With 55%-65% of potential in-network referrals lost due to health system leakage,1 improving continuity across the patient journey becomes a critical challenge. The Viz Pulmonary Suite, which integrates seamlessly with EHR systems, is designed to help pulmonary teams improve retention and outcomes by combi
Xsolla Showcases Industry Insights and Regional Commitment at Digital Dragons 202614.5.2026 15:00:00 CEST | Press release
Reinforcing Commitment To Eastern Europe Alongside New Industry Insights Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its participation in Digital Dragons 2026, one of Europe’s premier game industry conferences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514302984/en/ Graphic: Xsolla As the video game industry continues to evolve, early indicators from Q1 2026 point to sustained momentum across key segments. Xsolla’s presence at Digital Dragons will reflect on several emerging themes shaping the market, including: The ongoing strength of live-service and hybrid monetization models Increased adoption of direct-to-consumer (D2C) strategies by developers and publishers Growing demand for localized payment solutions to support global player bases A heightened focus on player engagement, retention, and community-building tools These insights unde
AS Graanul Invest Appoints Energy Industry Veteran Lars Christian Bacher as Chief Executive Officer14.5.2026 14:45:00 CEST | Press release
ASGraanul Invest (“Graanul” or the “Company”), Europe’s largest producer of sustainable wood pellets used for electricity and heat production, today announces energy industry veteran Lars Christian Bacher will be joining the business as Chief Executive Officer, effective 18 May. Bacher will drive the Company’s growth across Europe as Graanul doubles down on its strategy to provide its customers with sustainable fuel to enable the production of renewable, dispatchable power and heat. Outgoing Chief Executive Nicholas Dottino will support Bacher with his transition to his new role as an advisor to Apollo on infrastructure and energy investments. Bacher joins Graanul having previously worked at Norwegian multinational energy company Equinor as a member of the Executive Committee for over eight years, including two years as Chief Financial Officer, where he had responsibility for managing financial operations and strategic planning. Prior to this, he was executive Vice President, Developme
Mobix Labs to Acquire U.S. Rare Earth and Critical Minerals Company Powering Defense and National Security14.5.2026 14:01:00 CEST | Press release
Proposed Acquisition Would Position Mobix Labs Inside Strategic U.S. Supply Chains Powering Defense, National Security, and AI Infrastructure Mobix Labs, Inc. (Nasdaq: MOBX) today announced it has signed a non-binding Letter of Intent to acquire Special Project Delivery LLC ("SPD"), a strategic infrastructure platform building sovereign U.S. supply chains for rare earth elements, critical minerals, and energy storage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514342224/en/ U.S.A F-35 Lightning II The proposed acquisition would expand Mobix Labs — already a supplier to advanced U.S. and allied defense and aerospace systems — directly into one of the world's most strategically important industrial sectors. Key Facts at a Glance~418 kilogramsof rare earth materials are estimated to be used in each F-35 Lightning II. ~4,500 kilogramsof rare earth materials are estimated to be used in each Virginia-class nuclear submarine
Enterprise AI Hits the Wall: NTT DATA Research Reveals Growing Privacy and Sovereignty Barriers14.5.2026 14:00:00 CEST | Press release
Demands for privacy and sovereignty expose limits of architectures built for centralized and borderless data flows. Data jurisdiction has become a core design parameter, shifting away from globally integrated systems to regionally bounded architectures. Organizations that redesign early are gaining a measurable edge in AI readiness and scale. NTT DATA, a global leader in AI, digital business and technology services, today released new research showing that enterprise AI is outgrowing the architecture and infrastructure beneath it as data privacy and sovereignty requirements tighten. The research finds a widening split between enterprises that are redesigning AI for control, locality and security, and organizations still layering AI into environments that were not built to support these requirements. For years, enterprise architecture moved data across systems, clouds, applications and borders with increasing speed and efficiency. AI is exposing the limits of that model. Sensitive data
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom